To view more free videos – visit www.oncologyeducation.com
Profiling of protein expression, gene copy variations and mutations identified clinically relevant alterations in 99% of sarcomas. Given the overexpression of TOPO2 in approximately 50% of sarcomas, its utility as a biomarker of sensitivity to anthracyclines should be studied, especially in relation to TP53 status in a tumor. Trials of agents like mTOR and PI3K inhibitors could benefit from designs in which patient selection is based on PTEN loss or PIK3CA mutations instead of sarcoma histology. The prognostic implications of the co-existence of TP53 mutations and PTEN loss in sarcomas is yet to be elucidated.